Federal regulators approved the first of a new class of cholesterol-lowering medicines, developed by Regeneron and Sanofi. The drug, called Praluent, provides a new option for high-risk heart patients.
from WSJ.com: US Business http://ift.tt/1OCNGh8
via IFTTT
No comments:
Post a Comment